Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.78 Insider Own30.86% Shs Outstand8.40M Perf Week6.96%
Market Cap21.01M Forward P/E- EPS next Y-1.40 Insider Trans0.00% Shs Float5.90M Perf Month16.59%
Income-14.98M PEG- EPS next Q-0.58 Inst Own6.88% Short Float0.28% Perf Quarter26.80%
Sales0.00M P/S- EPS this Y-4.64% Inst Trans12.55% Short Ratio0.19 Perf Half Y17.14%
Book/sh1.10 P/B2.24 EPS next Y27.15% ROA-87.86% Short Interest0.02M Perf Year35.16%
Cash/sh1.14 P/C2.16 EPS next 5Y- ROE-98.06% 52W Range1.56 - 4.08 Perf YTD39.77%
Dividend Est.- P/FCF- EPS past 5Y56.03% ROI-159.14% 52W High-39.71% Beta1.47
Dividend TTM- Quick Ratio6.70 Sales past 5Y0.00% Gross Margin- 52W Low57.69% ATR (14)0.17
Dividend Ex-Date- Current Ratio6.70 EPS Y/Y TTM2.83% Oper. Margin0.00% RSI (14)58.75 Volatility6.91% 6.18%
Employees7 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q10.94% Payout- Rel Volume0.14 Prev Close2.34
Sales Surprise- EPS Surprise21.05% Sales Q/Q- EarningsMay 08 BMO Avg Volume86.77K Price2.46
SMA2012.36% SMA506.46% SMA2009.08% Trades Volume12,318 Change5.13%
May-22-24 08:00AM
May-08-24 12:54PM
Apr-11-24 07:30AM
Mar-28-24 08:00AM
08:30AM Loading…
Mar-25-24 08:30AM
Mar-18-24 08:00AM
Mar-13-24 07:30AM
Mar-04-24 07:30AM
Feb-15-24 08:00AM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-06-23 04:01PM
Oct-31-23 09:01AM
08:00AM Loading…
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 08:00AM
Sep-06-23 08:05AM
Aug-14-23 08:00AM
Aug-10-23 08:45AM
Aug-07-23 08:00AM
Jun-15-23 08:00AM
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
Apr-20-23 04:05PM
Apr-19-23 09:28AM
08:05AM Loading…
Apr-17-23 08:00AM
Mar-22-23 08:00AM
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Glen R.10% OwnerAug 14 '23Buy2.3423,93456,0061,190,400Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 11 '23Buy2.1235,06474,3361,166,466Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 10 '23Buy1.9444,35486,0471,131,402Aug 16 06:01 PM